非酒精性脂肪性肝病的饮食治疗热点

doi:10.3969/j.issn.1672-5069.2017.05.006

摘要/Abstract

Key words: Nonalcoholic fatty liver diseases, Nutrition, Diet, Weight loss, Treatment

李燕王彩花. 非酒精性脂肪性肝病的饮食治疗热点[J]. 实用肝脏病杂志, 2017, 20(5): 529-531.

Li Yan，Wang Caihua.. Hot spots in dietary therapy in patients with non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 529-531.

[1] Africa JA，Newton KP，Schwimmer JB. Lifestyle interventions including nutrition，exercise，and supplements for nonalcoholic fatty liver disease in children. Dig Dis Sci，2016，61（5）:1375-1386.
[2] Younossi ZM，Koenig AB，Abdelatif D，et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence，incidence，andoutcomes.Hepatology，2016，64（1）:73-84.
[3] Fan JG，Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol，2009，50（1）:204-210.
[4] Chalasani N，Younossi Z，Lavine JE，et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association，American Association for the Study of Liver Diseases，and American College of Gastroenterology. Gastroenterology，2012，142（7）:1592-609.
[5] Rinella ME. Nonalcoholic fatty liver disease:a systematic review. JAMA，2015，313（22）:2263-2273.
[6] Ratziu V，Goodman Z，Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol，2015，62（Suppl 1）:S65-75.
[7] Fan JG，Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterolo Hepatol，2013，28 （Suppl 4）:81-87.
[8] Huang D，Dhawan T，Young S，et al. Fructose impairs glucose-induced hepatic triglyceride synthesis. Lipids Health Dis，2011，10:20.
[9] Jegatheesan P，De Bandt JP. Fructose and NAFLD:The multifaceted aspects of fructose metabolism. Nutrients，2017，9（3）:[ahead of print].
[10] Abdelmalek MF，Suzuki A，Guy C，et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology，2010，51（6）:1961-1971.
[11] Chung M，Ma J，Patel K，et al. Fructose，high-fructose corn syrup，sucrose，and nonalcoholic fatty liver disease or indexes of liver health:a systematic review and meta-analysis. Am J Clin Nutrit，2014，100（3）:833-849.
[12] Chiu S，Sievenpiper JL，de Souza RJ，et al. Effect of fructose on markers of non-alcoholic fatty liver disease（NAFLD）:a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutrit，2014，68（4）:416-423.
[13] Mosca A，Nobili V，De Vito R，et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol，2017，66（5）:1031-1036.
[14] Perreault L，Pan Q，Mather KJ，et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk：results from the Diabetes Prevention Program Outcomes Study. Lancet，2012，379（9833）:2243-2251.
[15] European Association for the Study of the L，European Association for the Study of D，European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol，2016，64（6）:1388-1402.
[16] Sears B. Comparison of the Atkins，zone，ornish，and LEARN diets for change in weight and related risk factors among overweight premenopausal women. Medscape Gen Med，2007，9（3）:57.
[17] Bielohuby M，Sisley S，Sandoval D，et al. Impaired glucose tolerance in rats fed low-carbohydrate，high-fat diets. Am J Physiol Endocrinol Metab，2013，305（9）:E1059-1070.
[18] Mahady SE，George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metab Clin Experiment，2016，65（8）:1172-1182.
[19] Rinella ME，Sanyal AJ. Management of NAFLD:a stage-based approach. Nat Rev Gastroenterolo Hepatol，2016，13（4）:196-205.
[20] Jump DB，Depner CM，Tripathy S，et al. Potential for dietary omega-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. Adv Nutrit，2015，6（6）:694-702.
[21] Ng M，Fleming T，Robinson M，et al. Global，regional，and national prevalence of overweight and obesity in children and adults during 1980-2013:a systematic analysis for the Global Burden of Disease Study 2013. Lancet，2014，384（9945）:766-781.
[22] Promrat K，Kleiner DE，Niemeier HM，et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology，2010，51（1）:121-129.
[23] Thoma C，Day CP，Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults:a systematic review. J Hepatol，2012，56（1）:255-266.
[24] Musso G，Cassader M，Rosina F，et al. Impact of current treatments on liver disease，glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease （NAFLD）:a systematic review and meta-analysis of randomised trials. Diabetologia，2012，55（4）:885-904.
[25] Qin J，Li R，Raes J，et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature，2010，464（7285）:59-65.
[26] Kovatcheva-Datchary P，Arora T. Nutrition，the gut microbiome and the metabolic syndrome. Best Prac Res Clin Gastroenterol，2013，27（1）:59-72.
[27] Al-Lahham SH，Roelofsen H，Priebe M，et al. Regulation of adipokine production in human adipose tissue by propionic acid. Eur J Clin Invest，2010，40（5）:401-407.
[28] Vajro P，Mandato C，Licenziati MR，et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediat Gastroenterol Nutrit，2011，52（6）:740-743.
[29] Eslamparast T，Poustchi H，Zamani F，et al. Synbiotic supplementation in nonalcoholic fatty liver disease:a randomized，double-blind，placebo-controlled pilot study. Am J Clin Nutrit，2014，99（3）:535-542.
[30] Birerdinc A，Stepanova M，Pawloski L，et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Therapeut，2012，35（1）:76-82.

非酒精性脂肪性肝病的饮食治疗热点

Hot spots in dietary therapy in patients with non-alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[5]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[6]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[7]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[8]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[9]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[10]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[11]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[12]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[13]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[14]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[15]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.